Simplifying Global Compliance
FDAnews Drug Daily Bulletin
FDA Takes Exelixis Cancer Drug Off Advisory Group Meeting, Approval Date Stays as Nov. 29
Aug. 31, 2012
Exelixis’ experimental cancer drug cabozantinib has been removed from the agenda of a Food and Drug Administration advisory committee meeting, the company said, but the drug’s potential approval date has not changed.
San Francisco Business Times
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing